Kaeley et al. Evaluation of success of RA treatment. 69% LDA, 17% MDA, 14% HDA. Common barriers - medication access 27%, non-adherence 20%, co-morbidities 20%, non-inflammatory pain 13% @rheumnow #ACR22 Abstr#0077 https://t.co/c7euuzSx1m https://t.co/9ZN14ph5kI